1. Home
  2. SKYE vs HUHU Comparison

SKYE vs HUHU Comparison

Compare SKYE & HUHU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • HUHU
  • Stock Information
  • Founded
  • SKYE 2012
  • HUHU 2015
  • Country
  • SKYE United States
  • HUHU China
  • Employees
  • SKYE N/A
  • HUHU N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • HUHU
  • Sector
  • SKYE Health Care
  • HUHU
  • Exchange
  • SKYE Nasdaq
  • HUHU NYSE
  • Market Cap
  • SKYE 115.9M
  • HUHU 106.3M
  • IPO Year
  • SKYE N/A
  • HUHU 2024
  • Fundamental
  • Price
  • SKYE $3.98
  • HUHU $7.35
  • Analyst Decision
  • SKYE Buy
  • HUHU
  • Analyst Count
  • SKYE 6
  • HUHU 0
  • Target Price
  • SKYE $16.60
  • HUHU N/A
  • AVG Volume (30 Days)
  • SKYE 2.2M
  • HUHU 49.3K
  • Earning Date
  • SKYE 08-08-2025
  • HUHU 02-22-2025
  • Dividend Yield
  • SKYE N/A
  • HUHU N/A
  • EPS Growth
  • SKYE N/A
  • HUHU N/A
  • EPS
  • SKYE N/A
  • HUHU N/A
  • Revenue
  • SKYE N/A
  • HUHU $18,149,244.00
  • Revenue This Year
  • SKYE N/A
  • HUHU N/A
  • Revenue Next Year
  • SKYE N/A
  • HUHU N/A
  • P/E Ratio
  • SKYE N/A
  • HUHU N/A
  • Revenue Growth
  • SKYE N/A
  • HUHU 8.47
  • 52 Week Low
  • SKYE $1.14
  • HUHU $2.95
  • 52 Week High
  • SKYE $7.47
  • HUHU $9.89
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 60.88
  • HUHU N/A
  • Support Level
  • SKYE $3.65
  • HUHU N/A
  • Resistance Level
  • SKYE $4.75
  • HUHU N/A
  • Average True Range (ATR)
  • SKYE 0.71
  • HUHU 0.00
  • MACD
  • SKYE 0.00
  • HUHU 0.00
  • Stochastic Oscillator
  • SKYE 48.55
  • HUHU 0.00

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About HUHU HUHUTECH INTL GROUP INC

HUHUTECH International Group Inc specializes in providing factory facility management and monitoring systems, including high-purity gas, chemicals and liquid system and factory management and control systems for industrial clients, who are mainly semi-conductor manufacturers and electronics manufacturers in China. The products and services are widely used by semi-conductor manufacturers, LED and micro-electronics factories, as well as some pharmaceutical, food and beverage manufacturers.

Share on Social Networks: